LOGIN  |  REGISTER
FILTER BY TOPIC:     Enrollment   Pre-Clinical   First Dose   Phase 1   Phase 1/2   Phase 2   Phase 2/3   Phase 3  

Merck’s Clesrovimab (MK-1654), an Investigational Respiratory Syncytial Virus (RSV) Preventative Monoclonal Antibody,...

October 17
Last Trade: 109.75 -1.78 -1.60

In the Phase 2b/3 trial, clesrovimab reduced RSV-associated hospitalizations (secondary endpoint) and RSV-associated lower respiratory infection hospitalizations (tertiary endpoint) by more than 84% and 90%, respectively, through 5 months Clesrovimab has the potential to become the...Read more


Tenaya Therapeutics Announces Updates on TN-201 Gene Therapy Program for MYBPC3-associated HCM

October 17
Last Trade: 2.15 0.46 27.22

Independent Data Safety and Monitoring Board Endorsed Dose Escalation and Broadening of Eligibility Criteria; Cohort 2 Now Enrolling Initial Data from Cohort 1 to be Reported in December 2024 Highlights Recently Presented Insights on Pediatric MYBPC3-associated HCM Disease...Read more


Aura Biosciences: Multiple Clinical Complete Responses Demonstrated Following Single Low Dose Administration of Bel-sar in...

October 17
Last Trade: 10.29 0.43 4.36

Clinical Complete Responses Observed in 4 out of 5 Patients in Subset of Patients with Low Grade Disease; Evidence of Bladder Urothelial Field Effect in Non-Target Tumors Favorable Safety Profile Observed; Only Grade 1 Drug-Related Adverse Events Reported in Less Than 10% of Patients...Read more


AbbVie: U.S. FDA Approves VYALEV™ (foscarbidopa and foslevodopa) for Adults Living with Advanced Parkinson's Disease

October 17
Last Trade: 188.57 -3.29 -1.71

VYALEV™ is the first and only subcutaneous 24-hour continuous infusion of levodopa-based therapy for the treatment of motor fluctuations in advanced Parkinson's disease Adults treated with VYALEV reported superior improvement in "on" time without troublesome dyskinesia, compared to oral...Read more


Avadel Pharmaceuticals Announces FDA Approval of LUMRYZ™ (sodium oxybate) Extended-Release Oral Suspension (CIII) for...

October 17
Last Trade: 13.92 0.72 5.45

LUMRYZ is the only FDA-approved once-at-bedtime oxybate treatment for cataplexy or excessive daytime sleepiness (EDS) in patients 7 years of age and older with narcolepsy Granted Orphan Drug Exclusivity in pediatric narcolepsy patients 7 years and older through October 16, 2031 DUBLIN, Oct....Read more


FLUBLOK® (Influenza Vaccine) US label updated with one of Sanofi's largest flu vaccine safety studies in pregnant individuals...

October 16
Last Trade: 54.86 0.29 0.53

US FLUBLOK label1 updated to incorporate new safety study in pregnant individuals New safety data involving more than 48,000 pregnant individuals published in American Journal of Obstetrics and Gynecology (AJOG) Global Reports Recombinant or inactivated flu vaccines are recommended by the U.S....Read more


Featured Stock

Astria Therapeutics

Astria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development...

CLICK TO LEARN MORE

Biggest Gainers

 
CompanyChangeLast Trade
Korro Bio 40.25 101.23 $80.01
ZIVO Bioscience 18.61 1,691.82 $19.71
Vertex Pharmaceuticals 14.43 2.98 $498.73
United Therapeutics 13.24 3.68 $372.81
Chemed 10.62 1.76 $612.59
Finch Therapeutics 10.20 566.67 $12.00
UnitedHealth 9.74 1.75 $566.03
Alnylam Pharmaceuticals 9.39 3.27 $296.75
Univerl Health Services 8.82 3.91 $234.16
Humana 8.74 3.39 $266.34
Veeva Systems 7.02 3.34 $217.02
Axsome Therapeutics 6.92 8.01 $93.35
Wave Life Sciences 6.05 70.68 $14.61
Arcellx 5.36 5.96 $95.27
HCA Healthcare 5.22 1.30 $406.48
23andMe 4.64 1,717.85 $4.91
Cigna 4.28 1.23 $353.12
HealthEquity 4.17 4.97 $88.00

Highest Volume

 
CompanyVolumeLast Trade
Molecular Templates 229,845,170 $0.93
Notable Labs 143,064,464 $0.38
Tonix Pharmaceuticals 90,356,456 $0.18
Gritstone bio 44,786,299 $0.05
Vyome 36,361,564 $0.22
Walgreens Boots Alliance 31,938,151 $10.66
NKGen Biotech 19,280,831 $0.70
Clover Health 16,963,218 $4.18
Kazia Therapeutics 16,743,358 $0.53
Pfizer 15,787,984 $29.27
Centene 13,221,216 $63.00
Geron 12,022,719 $4.06
Carmell 10,445,802 $0.48
Windtree Therapeutics 10,416,364 $0.99
Tempest Therapeutics 10,228,745 $1.15
Amicus Therapeutics 10,184,206 $11.97
Novavax 9,795,124 $10.35
Humacyte 9,568,419 $4.86
Elevance Health 8,245,362 $444.35
  • Upcoming FDA Catalysts

    • Iterum Therapeutics (NASDAQ: ITRM) PDUFA Date

      October 25, 2024
    • PTC Therapeutics (NASDAQ: PTCT) PDUFA Date

      November 13, 2024
    • Autolus Therapeutics (NASDAQ: AUTL) PDUFA Date

      November 16, 2024
    • Applied Therapeutics (NASDAQ: APLT) PDUFA Date

      November 28, 2024
    • Applied Therapeutics (NASDAQ: APLT) PDUFA Date

      November 28, 2024
    • BridgeBio Pharma (NASDAQ: BBIO) PDUFA Date

      November 29, 2024

Featured Stock

Terns Pharmaceuticals

Terns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including a small-molecule GLP-1 receptor...

CLICK TO LEARN MORE

Featured Stock

Recursion

Recursion is a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery. Enabling its mission is the Recursion OS, a platform built across diverse technologies that continuously expands one of the world’s largest proprietary biological and chemical datasets...

CLICK TO LEARN MORE

Featured Stock

Surmodics

Viking Therapeutics is a clinical-stage biopharmaceutical company focused on the development of novel first-in-class or best-in-class therapies for the treatment of metabolic and endocrine disorders, with three compounds currently in clinical trials. Viking’s research and development activities leverage...

CLICK TO LEARN MORE

Featured Stock

ClearPoint Neuro

ClearPoint Neuro is a global therapy-enabling platform company providing stereotactic navigation and delivery to the brain. Applications of our ClearPoint Neuro Navigation System include electrode lead placement, placement of catheters, and biopsy. The platform has FDA clearance and is...

CLICK TO LEARN MORE

Invest In Early-Stage Biotech Opportunities

  • Explore venture capital investment opportunities in the healthcare industry and gain direct access to deal flows

  • Private placement shares can generally be purchased at a discount to market prices and have purchase warrants attached to them

  • If the underlying share price rises, warrants can be exercised to further build positions and enhance gains

  • Sign up to receive notifications of future early-stage investment opportunities:

COPYRIGHT ©2023 HEALTH STOCKS HUB